Crohn's Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Crohn's Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Crohn's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
' Crohn's Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn's Disease Market.
Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).
Some of the key takeaways from the Crohn's Disease Pipeline Report:
Companies across the globe are diligently working toward developing novel Crohn's Disease treatment therapies with a considerable amount of success over the years.
Crohn's Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn's Disease treatment
Emerging Crohn's Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn's Disease market in the coming years.
In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), after receiving FDA approval in December 2024. STEQEYMA is authorized for the same indications as STELARA, ensuring reliable treatment options for both patients and healthcare providers.
In March 2025, Johnson & Johnson announced that the FDA has approved TREMFYA® (guselkumab), making it the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition affecting the gastrointestinal tract.
In February 2025, Eli Lilly shared findings from the VIVID-2 open-label extension study at the Crohn's and Colitis Congress (CCC), revealing that most patients with moderately-to-severely active Crohn's disease treated continuously with OMVOH for two years achieved sustained clinical and endoscopic outcomes, including 43.8% of patients who had previously failed biologic therapies.
In January 2025, The FDA approved OMVOH (mirikizumab) for Crohn's disease, reinforcing the role of IL-23 inhibitors. Demonstrating robust long-term effectiveness, OMVOH is also under investigation for use in pediatric patients, potentially fulfilling a critical unmet need in this group.
Crohn's Disease Overview
Crohn's Disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, most commonly affecting the small intestine and the beginning of the colon. It can lead to symptoms such as abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. The exact cause is unknown but is believed to involve an abnormal immune response, genetics, and environmental factors. Crohn's can affect any part of the gastrointestinal tract and may lead to complications like strictures, fistulas, or bowel obstruction. While there is no cure, treatments including medications, dietary changes, and sometimes surgery can help manage symptoms and inflammation.
Emerging Crohn's Disease Drugs Under Different Phases of Clinical Development Include:
MORF 057: Morphic Therapeutic
OTL-104: Orchard Therapeutics
TP-317: Thetis Pharmaceuticals
AZD 7798: AstraZeneca
IMU 856: Immunic
CBP-307: Suzhou Connect Biopharmaceuticals
PF-06651600: Pfizer
Deucravacitinib: Bristol-Myers Squibb
E6011: Eisai Inc
Guselkumab: Janssen Pharmaceutical
Mirikizumab: Eli Lilly and Company
Filgotinib: Gilead Sciences
RHB-104: RedHill Biopharma
Ozanimod: Celgene Corporation
Brazikumab: AstraZeneca
Crohn's Disease Route of Administration
Crohn's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Crohn's Disease Molecule Type
Crohn's Disease Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Crohn's Disease Pipeline Therapeutics Assessment
Crohn's Disease Assessment by Product Type
Crohn's Disease By Stage and Product Type
Crohn's Disease Assessment by Route of Administration
Crohn's Disease By Stage and Route of Administration
Crohn's Disease Assessment by Molecule Type
Crohn's Disease by Stage and Molecule Type
DelveInsight's Crohn's Disease Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Crohn's Disease product details are provided in the report. Download the Crohn's Disease pipeline report to learn more about the emerging Crohn's Disease therapies
Some of the key companies in the Crohn's Disease Therapeutics Market include:
Key companies developing therapies for Crohn's Disease are - Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others.
Crohn's Disease Pipeline Analysis:
The Crohn's Disease pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Crohn's Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn's Disease Treatment.
Crohn's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Crohn's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Crohn's Disease Pipeline Market Drivers
High prevalence of Crohn's Disease, increase in Drug Development for Crohn's treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn's Disease Market.
Crohn's Disease Pipeline Market Barriers
However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn's Disease Market growth.
Scope of Crohn's Disease Pipeline Drug Insight
Coverage: Global
Key Crohn's Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others
Key Crohn's Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others
Crohn's Disease Therapeutic Assessment: Crohn's Disease current marketed and Crohn's Disease emerging therapies
Crohn's Disease Market Dynamics: Crohn's Disease market drivers and Crohn's Disease market barriers
Table of Contents
1. Crohn's Disease Report Introduction
2. Crohn's Disease Executive Summary
3. Crohn's Disease Overview
4. Crohn's Disease- Analytical Perspective In-depth Commercial Assessment
5. Crohn's Disease Pipeline Therapeutics
6. Crohn's Disease Late Stage Products (Phase II/III)
7. Crohn's Disease Mid Stage Products (Phase II)
8. Crohn's Disease Early Stage Products (Phase I)
9. Crohn's Disease Preclinical Stage Products
10. Crohn's Disease Therapeutics Assessment
11. Crohn's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Crohn's Disease Key Companies
14. Crohn's Disease Key Products
15. Crohn's Disease Unmet Needs
16 . Crohn's Disease Market Drivers and Barriers
17. Crohn's Disease Future Perspectives and Conclusion
18. Crohn's Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 days ago
- Globe and Mail
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Tempus AI TEM, a Chicago-based company focused on precision medicine, is building network effects via its three interconnected product lines. In the first quarter of 2025, revenues in its Data and Services segment increased 43.2% year over year to $61.9 million, driven by a 58% growth in Insights, the company's data licensing business. Gross profit outpaced revenue growth, up 65.2% with only a modest 3% increase in the cost of revenues. The business has scaled significantly, securing deals with companies like Novartis, Merck EMD, Takeda and United Therapeutics over the past year. Against that backdrop, Tempus' ability to sustain such strong growth rates in Data and Services is particularly impressive. Most of these contracts span multiple years, with total remaining contract value reflecting data and services yet to be delivered. Several recent developments are setting the stage for the momentum to continue. A major highlight is Tempus AI's $200 million data and modeling license agreement with AstraZeneca AZN and Pathos to build the world's largest foundation model, bringing AZN's total remaining contract value to over $1 billion as of April 30. AZN and Pathos are also covering a large portion of the compute costs to train the model. Notably, the agreement's non-exclusive nature allows Tempus to license data and build models with others in the future. The company also expanded its collaboration with Illumina, which will use its multimodal data platform to accelerate clinical benefits of molecular profiling across all major diseases. In May, Tempus inked a large data agreement with Boehringer Ingelheim focused on biomarker development and novel discovery efforts, building on their past collaboration. Further, the company's new oncology-focused platform, Loop, is already in use by a large pharmaceutical company to prioritize drug targets in patient subpopulations with severe unmet needs. TEM's Key Competitors in Data and Services ICON ICLR, an Ireland-based contract research organization, experienced a significant increase in overall biotech opportunities and a modest uptick in project win rates in the first quarter of 2025. However, it was ultimately offset by an increased number of customer-cancelled request for proposal (RFP) opportunities. In large pharma, RFP opportunities were softer in the quarter; still, ICLR's high success rate underscored its strong positioning as a strategic partner. IQVIA 's IQV Technology & Analytics Solutions business continued the strong recovery trend in the first quarter of 2025, with clients launching new drugs and executing their commercial roadmaps. However, IQV faced slower decision-making from clinical customers on new programs, reflecting broader macroeconomic pressure and industry caution. IQVIA reported a 10% increase in average time from RFP issuance to award in the quarter, both year over year and sequentially. TEM Outperforms Peers, Industry, But Valuation Stretched Year to date, Tempus AI shares have surged 102.5%, outperforming the industry's 18% growth and also delivering stronger returns than IQV and ICLR. Image Source: Zacks Investment Research TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.47X compared to the industry average of 5.83X. Image Source: Zacks Investment Research TEM Stock Estimate Trend As you can see, earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture. TEM stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report ICON PLC (ICLR): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report Tempus AI, Inc. (TEM): Free Stock Analysis Report This article originally published on Zacks Investment Research (
CTV News
3 days ago
- CTV News
Nova Scotia Health asks for help locating missing patient in Guysborough County
Barrett Fraser is pictured in a handout photo from Nova Scotia Health. Nova Scotia Health is asking the public for help in locating a missing patient. Barrett Fraser, 43, is missing from an address in Guysborough County, according to a news release from the health authority. Fraser is described at five-foot-nine, 214 pounds, with short brown and grey hair and a brown and grey beard. 'The patient's risk to himself and others increases with the length of time he is away from treatment,' reads the release. Nova Scotia Health asks anyone with information about the missing patient to contact their local law enforcement agency. For more Nova Scotia news, visit our dedicated provincial page
CBC
3 days ago
- CBC
Disability tax credits are critical for some Canadians. But applying for them can cost thousands
Social Sharing When Kathy Meyers heard she could get money back from the Canada Revenue Agency (CRA) through the disability tax credit, she was excited — but the prospect of filling out forms alongside her doctor felt like another burden to her already demanding days. Meyers, a Port Coquitlam, B.C., resident, has Crohn's disease. Her condition is severe — even with an ileostomy and the removal of her colon, she frequents the hospital for months at a time, and is on permanent disability as she is unable to work. So when a friend recommended True North Disability Services to handle the disability tax credit (DTC) applications for Meyers and her 14-year-old son, it felt like a perfect fit. Her husband, who is also disabled, plans to file an application on his own, after his doctor refused to work with a DTC advocacy company. More than a year since she first hired True North, Meyers is still awaiting the outcome of her application. But for her son's successful return, the family was billed more than $7,600 by the company — 20 per cent of the money they received from the CRA, plus GST. According to 2018 figures from the CRA, these businesses charge people anywhere from 15 to 40 per cent in contingency fees for their services. That's money Meyers says could have gone a long way for her low-income family, as the funds they received from the CRA have so far gone right back out the door to pay bills and debts. It also comes on top of two $150 fees she still owes her doctor, who was responsible for filling in all but two of the 16-page DTC forms for both Meyers and her son. Meyers says she regrets using a DTC company — especially now knowing free alternatives exist. "It's been very stressful and financially it's been very hard," Meyers said. "I think they're abusing the people that are in need of obtaining this disability tax credit because they're taking such a big chunk of the rebate." The CRA estimates applications for the DTC will triple in the next five to six years because it's the main requirement to get the new monthly $200 Canada Disability Benefit, which will begin payments in July. But there remains limited awareness of free or lower cost help — with many people turning to True North and other DTC advocacy companies that offer to simplify the application process for a percentage of the return. DTC companies say their fees — which are only charged in the case of successful applications — are critical to fund support for filing DTC applications, and also to fuel their advocacy for clients to the CRA and medical professionals. Along with non-profits and other groups that provide free help, there are other services that charge a flat rate fee, typically a few hundred dollars. Former MP Carla Qualtrough, who pushed for the creation of the Canada Disability Benefit in her time as minister of employment, workforce development and disability inclusion, is critical of the DTC application system — and the companies that profit from money intended for people with disabilities. She says hearing about what Meyers's family is facing is heartbreaking. "It feels like people are being taken advantage of," she said. "It's really frustrating to me, because the whole point of these benefits is poverty reduction, is helping people pay for the things they desperately need, and then they are being charged thousands and thousands of dollars." The federal government has attempted to limit the fees to $100 — but an injunction from the B.C. Supreme Court in 2021 halted this, following a legal challenge by True North and its co-founder Shane Nercessian. A trial has been scheduled for July 2026. DTC companies rely on fees When reached by the CBC over the phone and email, Nercessian declined interview requests. The 2021 injunction ruling described Nercessian's argument against restricting fees. "Mr. Nercessian deposes that the $100 maximum fee cap as set out in the Regulation would only cover basic data entry and processing, leaving little to no room to assist with issues involving eligibility, advocacy on behalf of the client … and work with the certifying health professional, and other associated services," reads the ruling. "In the result, most, if not all, DTC companies will be driven out of business as it will no longer be economical to provide many DTC services." The ruling also provides an overview of the services True North provides for clients, including a 10-year tax assessment, explaining the application and eligibility criteria to medical professionals, and filing objections if clients are "unjustly denied." In an email to the CBC, Nercessian said True North is part of the Disability Tax Fairness Alliance and played a "pivotal role" in exposing issues with insulin-dependent diabetics being denied benefits. There are former clients who say they are grateful for True North's help with their applications, such as Kathy Johnson, a resident of Blue River, B.C. About $1,900 of the more than $9,000 she received back from the DTC went to True North. Though Johnson wasn't aware of free options prior to applying, she didn't feel she had the time and energy to do it herself — and says she would recommend True North to others. "Really, I do have no regrets," she said. Others do have regrets, like Leanne King, who has diabetes and polycystic kidney disease. She says she likely wouldn't have spent $3,850 with True North if she had known alternatives existed. "I just wasn't capable at the time of managing all that they did," she said. "I do think it's a lot [of money], and I do think it's a little bit predatory, because they're dealing with people that are sick." Medical experts call for application to be streamlined The Canadian Medical Association, Doctors of B.C. and disability advocates are among those calling for the DTC process to be simplified, to reduce the burden on both medical professionals and people with disabilities. Dr. Charlene Lui, president of Doctors of B.C., says the time-consuming forms cause "significant moral distress for all physicians," as it takes them away from patients who already have limited access to doctors. "Ideally, the form would be shortened, made easier to fill out, and be embedded within the electronic record," said Lui. The CRA says it "significantly overhauled" the application process by digitizing it in 2023, sparked by concerns in the medical industry. When asked about whether it may streamline further with suggestions posed by Lui — such as accepting a doctor's note or forms compatible with existing files — the CRA said it is bound by legislation. "The CRA continues its efforts to make the DTC more accessible, aligning with the [Disability Advisory Committee's] recommendations to ensure that individuals with disabilities can access the credit without financial burden," the statement reads. Minister of Jobs and Families Patty Hajdu was unavailable for an interview, and her office did not respond to specific questions from the CBC. The ministry said Canada is funding $23.5 million for six disability non-profits to help people access benefits including the DTC for free, and $243 million to eliminate out-of-pocket fees for medical providers to fill out DTC forms. "The Government of Canada has committed to further reviewing and reforming the process to apply for the Disability Tax Credit," said the ministry in a statement. To Qualtrough, the issue lies with the lack of a consistent approach to disability support in Canada. Ideally, she says, people should be able to undergo a one-step process to access all provincial and federal disability benefit programs. "We're asking tax analysts to decide and serve as the gatekeepers for these really important social benefits, it's just not the right fit," she said.
